Navigation Links
Celebrex May Reduce Levels of Lung Cancer Biomarker
Date:6/1/2008

Anti-inflammatory might one day help prevent malignancies, study suggests

SUNDAY, June 1 (HealthDay News) -- A widely prescribed pain reliever may one day have value in helping to prevent lung cancer.

Researchers report that Celebrex (celecoxib), the last remaining cox-2 inhibitor on the U.S. market, may reduce levels of a biomarker indicating risk for this deadly disease. The team presented its findings Sunday at the American Society of Clinical Oncology annual meeting in Chicago.

They stressed that this doesn't mean people should start taking the drug for this reason, as Celebrex has noted cardiovascular side effects, albeit effects that were not seen in this short-term study.

"This is a very early study," said Dr. Shakun Malik, director of the lung cancer program at Georgetown's Lombardi Cancer Center, in Washington, D.C. "It hasn't shown any effect on actual lung cancer. All it is showing is that it affects biomarkers. The hypothesis is that if biomarkers are affected, it will help, but we haven't shown that as of yet."

The researchers agreed.

"We cannot sit here and say that taking celecoxib is going to prevent lung cancer," said study author Dr. Edward S. Kim, M.D., an assistant professor of thoracic head and neck medical oncology at the University of Texas M.D. Anderson Cancer Center in Houston. "What we do know was that Celebrex, when taken over a three- or six-month period, was safe to administer even at a higher dose of 800 milligrams daily."

"We certainly need to move forward with prospective validation," added Kim, who spoke at a Sunday news conference. In particular, researchers need to verify if reductions in biomarkers actually translate into a reduction in the risk of developing malignancies in the lung.

"It's too early to tell, but we're definitely interested in other trials to see how they make out with survival,' said Dr. Karen Reckamp, an assistant professor of medicine at City of Hope Cancer Center in Duarte, Calif.

Lung cancer is a notoriously difficult-to-treat disease, largely because it's usually not caught in its early stages.

"Lung cancer is an extraordinarily challenging tumor type," confirmed Dr. Howard Sandler, moderator of the news conference and a professor of radiation oncology and urology at the University of Michigan.

Prevention, therefore, becomes key. Quitting smoking or never smoking, of course, greatly reduces the risk for this disease. But there are people who beat the odds even if they smoke, just as there are nonsmokers who do develop lung cancer.

"We need to continue to refine what a high-risk population is, both clinical and biological characteristics, and that leads us into biomarkers," Kim said. The researchers were primarily interested in how Celebrex might affect Ki-67, a protein that may be related to cell proliferation.

The cox-2 enzyme is expressed in both precancerous lesions in lung tissue, as well as in lung cancer, and it has an inflammatory aspect that can stimulate more cell growth within the lung.

This study involved more than 200 patients, all of whom had a history (current or prior) of a greater than 20-pack-years cigarette habit. All participants underwent biopsies at the opening of the study, at three months and again at six months.

They were then randomized to take either Celebrex or a placebo for three months, after which they either continued on that course or switched to the other arm.

Over three months, high-dose Celebrex (400 milligrams twice a day) did reduce expression levels of Ki-67, as well as the cox-2 enzyme and a third biomarker, NF-kappa-B.

The effect was seen in both current and former smokers but was stronger in current smokers, Kim said.

No cardiac side effects were seen in the group, although previous research showed a benefit to Celebrex in reducing colon cancer but, at the same time, a significant increase in adverse events.

Kim hopes that future studies will identify patients at higher risk for heart problems (the greatest risk factor is age), and take that into account. It's also unclear at this point how long individuals should take Celebrex.

As for patients who already have the disease, Kim said, "I hope we can keep you alive until you have a heart attack, because that means we have treated your lung cancer very well."

Another study also presented at the meeting found that PET/CT (positron emission tomography/computed tomography) imaging more accurately staged lung cancer cases, sparing more patients from inappropriate surgery.

PET imaging identified 14 percent of patients who had cancer too advanced for surgery, while conventional work-ups only identified 7 percent of such patients for whom surgery would have been inappropriate.

"PET can replace conventional tagging in early stage non-small cell lung cancer," said study investigator Dr. Donna E. Maziak, of the Ontario Clinical Oncology Group in Hamilton, Ontario.

More information

Visit the National Cancer Institute for more on lung cancer.



SOURCES: June 1, 2008, news conference with Edward Kim, M.D., assistant professor, thoracic head and neck medical oncology, University of Texas M.D. Anderson Cancer Center, Houston, and Donna E. Maziak, M.D.C.M., Ontario Clinical Oncology Group, Hamilton, Ontario, Canada; Shakun Malik, director, lung cancer program, Lombardi Cancer Center, Georgetown University, Washington, D.C.; Karen Reckamp, assistant professor, medicine, City of Hope Cancer Center, Duarte, Calif.; June 1, 2008, presentations, American Society of Clinical Oncology annual meeting, Chicago


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Celebrex-Lipitor combo may halt prostate cancer
2. Celebrex Plus Lipitor Could Fight Prostate Cancer
3. Celebrex, Naproxen Wont Prevent Mental Decline
4. Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial
5. New study: Pine bark reduces perimenopausal symptoms
6. Different method of evaluating the urinary tract system reduces radiation dose
7. Saline Reduces Mortality for Brain Injury Patients
8. New approaches to reduce scarring
9. Fruity vegetables and fish reduce asthma and allergies
10. New study: Pine bark extract reduces ADHD symptoms in children
11. New Case Study Details How an Illinois Hospital Created a Safe Lifting Team that Dramatically Reduced Injuries, Increased Staff Satisfaction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... The Woodlands at ... offering a new model of care for living and healing, celebrated its grand opening, ... Life in a Real Home provided by Empowered Staff. , “This is an incredibly ...
(Date:5/26/2016)... Warner, New Hampshire (PRWEB) , ... May 26, 2016 , ... ... of which are designed, engineered, and manufactured in Warner, New Hampshire at the MadgeTech ... known to provide reliable monitoring solutions trusted by government agencies, including NASA. , ...
(Date:5/26/2016)... SURPRISE, ARIZ. (PRWEB) , ... May 26, 2016 , ... ... worry of American families. , The 550 employees of Sun Health Senior Living ... plan through Aetna that reduces their doctor and prescription copays for the year, while ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership of Life Science Logistics ... organization has earned its ISO 13485 certification, indicating the company’s quality control system ... and policies associated with ISO quality standard 13485. , BSI Group America, ...
(Date:5/26/2016)... ... May 26, 2016 , ... North Cypress Medical Center hosted ... Club in Cypress. With the help of community partners, the event organizers raised $45,000 ... hope for wounded service members and their families through health, wellness, and therapeutic support. ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... May 24, 2016   ... beide primären Endpunkte und demonstriert Ebenbürtigkeit ... ‚ausgezeichneter plus guter , ... ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... neue positive Daten von der MORA-Studie der Phase ...
(Date:5/24/2016)... New Zealand , May 24, 2016 ... and informatics solutions for the healthcare sector, has been named ... New Zealand Hi-Tech Awards 2016. Dr Bruce ... fantastic acknowledgement for our team.  It,s really good to be ... burden healthcare internationally. Our products are used in 35 countries ...
(Date:5/24/2016)... VMS BioMarketing as senior vice president of sales, announced Andrea Heslin Smiley , ... the company,s business development and sales team, exploring new opportunities for VMS to empower ... ... ... ...
Breaking Medicine Technology: